Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
Key facts
- Who runs it
- Scandinavian Critical Care Trials Group
- Where
- Denmark and Sweden22 sites in 2 countriesChoose a country to see its sites
- Trial code
- NCT06184659
- EU 2023-509703-33-00
- U1111-1301-6379
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 5,800 people, planned
- Started
- 26 Jun 2025
- Expected to end
- 30 Mar 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Meropenem
- Piperacillin/Tazobactam
- Record updated
- 3 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age ≥ 18 years
- Sepsis (including septic shock) defined according to the Sepsis-3 criteria (1), i.e., suspected or documented infection and an acute increase of ≥ 2 points in the Sequential Organ Failure Assessment (SOFA) score (a marker of acute organ dysfunction)
- Critical illness defined as use of at least one of the following:; Invasive mechanical ventilation; Non-invasive ventilation; Continuous use of continuous positive airway pressure (CPAP) for hypoxia; Oxygen supplementation with an oxygen flow of ≥ 10 litres (L)/minute independent of delivery system and total flows; Continuous infusion of any vasopressor or inotrope (excluding strictly procedure-related infusions)
- Clinical indication for empirical treatment with either meropenem or piperacillin/tazobactam
Who cannot take part
- Preceding intravenous treatment with meropenem or piperacillin/tazobactam for \> 24 hours prior to screening
- Known infection/colonialization with microorganism with acquired resistance against meropenem or piperacillin/tazobactam within the previous 3 months (e.g., ESBL-, AmpC- or carbapenemase-producing bacteria)
- Previously randomised into the EMPRESS trial
- Known hypersensitivity or allergy to beta-lactam antibiotics
- Suspected or documented central nervous system infection
- Fertile women \< 60 years of age with known pregnancy or positive urine human gonadotropin (hCG) or plasma hCG
- Current or planned use of valproate within 30 days from randomisation
- Patient included in another interventional trial where co-enrolment with EMPRESS is not permitted
- Informed consent following inclusion expected to be unobtainable
- Patient under coercive measures
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.
The 2 groups in the trial
- MeropenemTreatment being tested
Participants in the experimental intervention arm will receive 1 g of IV meropenem three times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
- Piperacillin/TazobactamExisting treatment, for comparison
Participants in the control arm will receive 4/0.5 g of intravenous piperacillin/tazobactam four times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial
- Publications
- Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial.Acta anaesthesiologica Scandinavica, 2026
- Record updated
- 3 July 2025